Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574295 | 0.92 | GPR119 (0.44) | GPR119CYP3A4 | |
| SCHEMBL2019585 | 0.92 | GPR119 (0.43) | GPR119CYP3A4 | |
| SCHEMBL2022039 | 0.90 | GPR119 (0.42) | GPR119CYP3A4 | |
| SCHEMBL2021367 | 0.89 | GPR119 (0.61) | GPR119CYP3A4 | |
| SCHEMBL2026661 | 0.82 | GPR119 (0.58) | GPR119CYP3A4 | |
| SCHEMBL2021355 | 0.81 | CYP3A4 (0.57) | GPR119CYP3A4 | |
| SCHEMBL12574298 | 0.80 | GPR119 (0.49) | GPR119CYP3A4 | |
| SCHEMBL3690185 | 0.79 | GPR119 (0.60) | GPR119 | |
| SCHEMBL2016797 | 0.79 | GPR119 (0.48) | GPR119CYP3A4 | |
| SCHEMBL2017626 | 0.78 | CYP3A4 (0.49) | GPR119CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | claimed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, GCKR, GID4 | GPR119 1/4885CYP3A4 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.